FLT3 and cancer: While numerous clinical studies have targeted NRF2 across various cancer types over the past three decades, none have specifically focused on FLT3-mutant AML [141,142], despite evidence suggesting that targeting NRF2 and antioxidant pathways may deplete leukemic stem cells (LSCs) [143,144].